No Data
No Data
Forecasting The Future: 4 Analyst Projections For Gritstone Bio
During the last three months, 4 analysts shared their evaluations of Gritstone Bio (NASDAQ:GRTS), revealing diverse outlooks from bullish to bearish.In the table below, you'll find a summary of their
Express News | JMP Securities Reiterates Market Outperform on Gritstone Bio, Maintains $5 Price Target
JMP Securities Maintains Gritstone Bio(GRTS.US) With Buy Rating, Maintains Target Price $5
JMP Securities analyst Roy Buchanan maintains $Gritstone Bio(GRTS.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 32.2% and a
Express News | Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Gritstone Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version EMERYVILLE, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccine
Gritstone Bio to Participate in Upcoming Investor and Scientific Conferences
PDF Version EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines,
No Data